COMP <GO>
TRXB vs FENC // EV/EBITDA & P/E VALUATION
TRex Bio Inc. (NASDAQ) VS. Fennec Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: TRXB 1
— FENC 1
■ METRIC PARITY
LAST: $13.52 (-6.31%) • MKT CAP: $371.1M
valuation
—
LAST: $10.95 (+0.74%) • MKT CAP: $383.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRXB VS. FENC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRXB | FENC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -25.90% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -3.25% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -14.10% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -6.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.31 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 45.5 | +2.81 | TRXB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $371.1M | $383.6M | -$12.6M | FENC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRXB REV | FENC REV | TRXB GROSS % | FENC GROSS % | TRXB FCF | FENC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $44.6M | — | — | — | -$12.5M |
| FY 2024 | — | $47.5M | — | — | — | $27.0M |
| FY 2023 | — | $21.3M | — | — | — | -$17.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRXB // BETA —
FENC // BETA —